ELYXYB Drug Patent Profile

« Back to Dashboard

Which patents cover Elyxyb, and what generic alternatives are available?

Elyxyb is a drug marketed by Scilex Pharms and is included in one NDA. There are six patents protecting this drug.

The generic ingredient in ELYXYB is celecoxib. There is one drug master file entry for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the celecoxib profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Elyxyb

A generic version of ELYXYB was approved as celecoxib by TEVA on May 30^th, 2014.

Summary for ELYXYB

US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	175
Patent Applications:	4,734
Drug Prices:	Drug price information for ELYXYB
What excipients (inactive ingredients) are in ELYXYB?	ELYXYB excipients list
DailyMed Link:	ELYXYB at DailyMed

See drug prices for ELYXYB

Pharmacology for ELYXYB

Drug Class	Nonsteroidal Anti-inflammatory Drug
Mechanism of Action	Cyclooxygenase Inhibitors

US Patents and Regulatory Information for ELYXYB

ELYXYB is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Scilex Pharms	ELYXYB	celecoxib	SOLUTION;ORAL	212157-001	May 5, 2020		RX	Yes	Yes	10,722,456		Y
Scilex Pharms	ELYXYB	celecoxib	SOLUTION;ORAL	212157-001	May 5, 2020		RX	Yes	Yes	9,795,620		Y
Scilex Pharms	ELYXYB	celecoxib	SOLUTION;ORAL	212157-001	May 5, 2020		RX	Yes	Yes	10,799,517		Y

EU/EMA Drug Approvals for ELYXYB

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Limited	Onsenal	celecoxib	EMEA/H/C/000466Onsenal is indicated for the reduction of the number of adenomatous intestinal polyps in familial adenomatous polyposis (FAP), as an adjunct to surgery and further endoscopic surveillance (see section 4.4).The effect of Onsenal-induced reduction of polyp burden on the risk of intestinal cancer has not been demonstrated (see sections 4.4 and 5.1)	Withdrawn	no	no	no	2003-10-17

International Patents for ELYXYB

See the table below for patents covering ELYXYB around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2016267685
Australia	2019203815
Brazil	112017025445

Supplementary Protection Certificates for ELYXYB

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0731795	10075033	Germany		PRODUCT NAME: CELECOXIB; NAT. REGISTRATION NO/DATE: 48802.00.00 20000518; FIRST REGISTRATION: SE 14838 19991203
2488169	C202330042	Spain		PRODUCT NAME: COCRISTAL DE TRAMADOL, OPCIONALMENTE EN FORMA DE UNA SAL FISIOLOGICAMENTE ACEPTABLE, Y CELECOXIB; NATIONAL AUTHORISATION NUMBER: 89051; DATE OF AUTHORISATION: 20230925; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 89051; DATE OF FIRST AUTHORISATION IN EEA: 20230925

Elyxyb (celecoxib? no) Market Dynamics and Financial Trajectory: Pricing, Uptake, Exclusivity, and Competitive Pressure

Last updated: July 24, 2026

Elyxyb market performance is not computable from patent-data alone. No drug-specific financial trajectory, payer pricing, sales run-rate, adoption milestones, or FDA/Orange Book execution facts are provided in the input, and generating them would require external commercial datasets not included here.

What is driving Elyxyb market dynamics: pricing, access, and utilization shifts?
No Elyxyb-specific market-dynamics inputs are available (pricing benchmark, formulary placement, utilization trend, reimbursement channel mix). Patent analysis cannot produce credible financial drivers without validated commercial and regulatory facts tied to the exact product.

What payer and reimbursement forces typically move Elyxyb sales?

• Formulary tiering and prior authorization requirements
• Step edits and age or severity restrictions
• Pharmacy benefit manager (PBM) contracting terms
• Wholesale acquisition cost (WAC) and net price trajectory
• Competitive reference coverage

No Elyxyb payer terms or contracting outcomes are provided, so the effect cannot be stated.

How has Elyxyb financial performance tracked over time: revenue curve, gross-to-net, and profitability?
No sales, revenue, or gross-to-net data for Elyxyb are provided. A financial trajectory requires at least one of: reported quarterly/annual revenue, analyst consensus, or verified payer-mix and pricing benchmarks.

What metrics define an Elyxyb financial trajectory?

• Net sales trend by quarter
• Gross-to-net components (rebates, discounts, chargebacks)
• Inventory and channel fill
• Underlying demand vs. pull-through
• SG&A and R&D burn relative to sales scale
• Cash burn and operating margin inflection

No such data points are provided for Elyxyb.

When does Elyxyb face exclusivity erosion: patent expirations, exclusivity windows, and generic entry timing?
No Elyxyb patent estate, listed expiration dates, exclusivity start/end dates, or Orange Book publication status are provided. A generic-entry timeline cannot be constructed.

What “exclusivity” typically includes in US drug commercialization

• Patent term (including any patent term adjustments)
• Non-patent regulatory exclusivities (for eligible products)
• Market exclusivity protections triggered by the approval pathway
• Litigation-driven delay from ANDA/paragraph IV suits

None of these are supplied for Elyxyb.

What patents protect Elyxyb and how strong is the patent estate for generics and biosimilars?
No patent numbers, assignees, filing/priority dates, claim scope, or challenge history are provided. Strength can’t be evaluated without the patent list and relevant claim categories (composition, formulation, method of use, manufacturing).

What to map in an Elyxyb patent landscape

• Composition-of-matter coverage on the active ingredient
• Salt/solvate and polymorph coverage
• Formulation and delivery system claims (if applicable)
• Method-of-use claims (dose, regimen, indication)
• Manufacturing process claims
• Pediatric exclusivity or other regulatory extensions (if any)
• Litigated patents and settlement terms (if any)

No Elyxyb patent identifiers are provided in the prompt.

Which companies are challenging Elyxyb: ANDA paragraph IV and potential launch rivals?
No paragraph IV filings, applicants, or litigation captions are provided for Elyxyb. Launch-risk profiling cannot be produced.

What to look for in Elyxyb generic entry risk

• ANDA filers with “NDA 1 to 10” or Paragraph IV certifications
• Carve-outs for formulation or method-of-use patents
• First-filer and settlement market-share impacts
• FDA approval readiness and manufacturing readiness signals

No inputs are provided.

What is the Orange Book status of Elyxyb: listed patents, expirations, and exclusivity expirations?
Orange Book status requires a listing snapshot (product, NDA number, patent list with expiration dates, exclusivity block entries). None is provided.

Orange Book table that must exist to answer this query

• Proprietary name
• NDA/BLA number
• Dosage form and strength
• Active ingredient and route
• Patent numbers
• Patent expiration dates (and any PTA/extension)
• Exclusivity expiration dates and type
• Orange Book update timestamps

No such data is included.

How does Elyxyb compare with competitive branded and generic options: market share and price erosion risk?
No Elyxyb competitive set is identified (same indication, same route, same class, same dosing frequency). Without comparators and their pricing/market share data, a competitive impact statement would be fabricated.

Typical competitive factors for ulcer? migraine? (unspecified here)

• Therapeutic equivalence and clinical outcomes
• Dosing convenience and adherence
• Safety and monitoring burden
• Formularies and prior authorization trends
• Manufacturer marketing intensity vs. competitor launches

No Elyxyb-specific facts are provided.

What manufacturing and formulation IP barriers affect Elyxyb generic viability?
No Elyxyb formulation details, process patents, or compliance hurdles are provided.

Common manufacturing/formulation barriers

• Tight particle size, crystallinity, or polymorph requirements
• Cross-linking or excipient processing controls
• Sterility and aseptic process constraints (if applicable)
• Stability windows and refrigerated storage constraints (if applicable)
• Bioavailability and bridging requirements

No such data is included.

What patent litigation affects Elyxyb and how do settlements impact revenue timing?
No litigation docket, settlement date, or stay terms are provided. Financial trajectory cannot be linked to litigation without those facts.

Litigation-to-commercial translation

• Automatic stay triggers (when applicable)
• Settlement “entry date” carve-outs
• License fee structure and royalty triggers
• Court-ordered injunction scope
• Design-around outcomes

No Elyxyb litigation facts are provided.

Key Takeaways

• Elyxyb market dynamics and financial trajectory cannot be derived from the provided input.
• No Elyxyb-specific patent estate, Orange Book listing, litigation, exclusivity dates, pricing, or sales metrics are available in the prompt to support a credible business assessment.

---

FAQs

1. What are the key FDA pathway milestones that typically shape Elyxyb launch timing and sales ramp?
2. How do Paragraph IV settlements typically influence Elyxyb first generic entry and net price trajectory?
3. What role does formulary placement play in adoption curves for Elyxyb versus class competitors?
4. Which patent claim types usually block generic substitution for top-selling Elyxyb dosage forms?
5. How does inventory channel behavior affect Elyxyb quarterly revenue recognition during early commercialization?

---

References (APA)

No sources were provided or cited in the prompt.